Lipid-lowering Effect of Plant Stanol Yogurt

• subjects must voluntarily sign the informed consent
• subjects must be male or female aged 20 to 70 years
• subjects must have a serum total cholesterol concentration of 5.2 - 7.5 mmol/l ( 205 - 290 mg/dl) at the screening visit (visit 1, -2 week)

Exclusion Criteria:

• subjects using lipid lowering medication
• subjects using ezetimibe
• subjects with bile acid sequestrant medication
• subjects with statin therapy
• subjects using other medication significantly influencing on lipid values
• subjects with diagnosis type 1 or type 2 diabetes
• severe obesity (BMI>35.0 kg/m2)
• serum fasting triglycerides > 4.0 mmol/l
• subjects with any hepatic or renal disorder according to medical history
• subjects who have history of myocardial infarction or unstable angina pectoris within six months prior to screening
• subjects who have history of coronary artery bypass graft or percutaneous transluminal coronary angioplasty within six months prior to screening
• subjects who have history of temporal ischemic attack or stroke within six months prior to screening
• subjects who have a history of cancer or other malignant disease within the past five years
• subjects with abnormal values of health screening variables measured at screening visit: serum gamma-glutamyltransferase> 2 x upper limit, serum alkaline phosphatase> 2 x upper limit or other abnormality in laboratory evaluations considered as clinically significant in the opinion of the study physician
• subjects who are consuming more than 15 portions of alcohol / week
• subjects who are pregnant or lactating
• subjects using Benecol, Becelpro.activ, Danacol or other plant sterol enriched products within 30 days before visit 2
• subjects with severe lactose intolerance, milk allergy or any other intolerance to the ingredients of test products
• celiac disease